Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 126

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 126
---
. While it is a fact that the earliest patent families are due to expire in the
next few years, we believe that the newest patent applications will provide protection to the updated products and processes for their
manufacture. The latest patent applications, some of which have matured to patents, are designed to protect various improvements to the
earliest filed patents, including improvements to the process of production, and ready to use formulations that may be administered from
pre-filled syringes and do not require in situ addition of activators prior to use.

The latest family of patent
applications is derived from WO 2017/103924 (granted in China, India and Israel and filed in other territories), and the objectives the
Company aims to achieve with these applications are to seek to obtain patent protection to cover improved compositions which are being
used or which may be used by the Company in the future. The improved compositions that the Company aims to protect with these applications
relate to otherhydrogels that are formed using Gelrin’s conjugates of polyethylene glycol and denatured fibrinogen. In particular,
the conjugates are generated using an improved process that avoids the use of potentially harmful polar organic solvents and are ready
for use (GelrinC). The family of patent applications derived from WO 2017/103924 are granted in China, CN 108472413, India, IN 457479
and Israel, IL 259891 and includes pending patent application Nos. US 2022/0105240, EP 3389736, CA 3006695, and JP 2023-180906, which
are detailed in the table below. The pending patent applications are still in different stages of examination and may not mature into
actual granted patents. Thus, there is a risk that if any one or more family members are not granted, the improved compositions will
not be patent protected in their respective territory.

GelrinV and GelrinP

A second “pipeline
product” of the Company is designated as GelrinV and it is a product using a conjugate of fibrinogen with a polaxamer (Pluronic)
for the treatment of osteoarthritis. The product exhibits thermo-reversible gelation, is water-immiscible and can be delivered using
a minimally invasive application. It is designed to a form of a paste in the cavity upon UVA irradiation.

This product is more viscous
and better suited for the